Chen Liu, MD, PhD, Is Named Chair of Pathology
Chen Liu, MD, PhD, has been chosen to be the next chair of the Department of Pathology at Yale School of Medicine and chief of Pathology at Yale New Haven Hospital, effective March 1, 2020. He comes from Rutgers Biomedical and Health Sciences in New Jersey.
International team discovers unique pathway for treating deadly children's brain cancer
An international team of researchers has discovered a new pathway that may improve success against an incurable type of children's brain cancer. The study results suggest that scientists have identified a unique way to disrupt the cellular process that contributes to Diffuse Intrinsic Pontine Gliomas (DIPG).
Solomon Center Student Fellows Advocate Against Proposed HHS Rule
A group student fellows from Yale Law School’s Solomon Center for Heath Law and Policy partnered with Yale School of Medicine (YSM) Dean’s Advisory Council on LGBTQI+ Affairs to submit comments to the U.S. Department of Health & Human Services on August 13, 2019, advocating against a proposed rule that they say would have harmful effects on both patients and providers.
Vilarinho and Wilson Win 2019 Clinical Scientist Development Awards
Yale School of Medicine Department of Internal Medicine’s Silvia Vilarinho, MD, PhD, assistant professor of medicine (digestive diseases) and of pathology, and Frederick Wilson, MD, PhD, assistant professor of medicine (medical oncology) and genetics, are winners of a 2019 Clinical Scientist Development Award (CSDA) from the Doris Duke Charitable Foundation (DDCF).
Dr. Richard Bucala named the Von Zedtwitz Professor
Dr. Richard Bucala, newly appointed as the Waldemar Von Zedtwitz Professor of Medicine, Pathology, and Epidemiology and Public Health, studies immune system regulation with a focus on how protective responses can lead to immunopathology and disease.
GENcast: A Biological GPS That Guides Awareness through Cellular Space
There’s no shame in contemplating how we managed to get around before GPS came to our phones. Some may argue that there is an overreliance on automation since maps have been a proven method of exploration and travel for centuries. Yet, access to technology like GPS has democratized travel and opened the door for society to explore our surroundings in ways few ever thought possible.
Yale Researchers Crack the Code of a Rare, Inherited Anemia
Yale pediatrician and geneticist Patrick Gallagher, M.D., studies hereditary spherocytosis (HS), an inherited disease associated with hemolytic anemia, when red blood cells are destroyed faster than they are produced due to abnormal membranes. A novel mutation in the gene that encodes alpha-spectrin, a protein essential for normal red blood cell membranes, is responsible for many cases of recessive hereditary spherocytosis (rHS), the most severe form of the disease, reports Gallagher’s team
Urine Biomarkers Could Improve Diagnosis of Serious Kidney Allergic Reaction
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis (AIN), an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.
Publication in the Journal Clinical Cancer Research Uses NanoString's GeoMx Digital Spatial Profiler to Discover Predictive Biomarkers for Immunotherapy
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a publication in the journal Clinical Cancer Research of a collaborative research study led by investigators from the Yale School of Medicine. This paper represents the fourth peer-reviewed publication to describe GeoMx DSP. The article, entitled “High-plex predictive marker discovery for melanoma immunotherapy treated patients using Digital Spatial Profiling,” used the GeoMx™ Digital Spatial Profiler (DSP) to identify biomarkers that were predictive for response to immunotherapy for the treatment of melanoma.